Featured Blogs

Artificial intelligence (AI) is transforming health care, offering ways to improve diagnostics, optimize treatment plans, and enhance patient outcomes. However, its rapid growth raises issues around privacy, safety, bias, and ethics, all of which require regulation. While current frameworks offer some level of oversight, Congress and the Administration have begun exploring new ways to regulate AI, especially in health care.Â
Key Areas of Focus for Congressional RegulationÂ
Data Privacy and SecurityÂ
AI systems require massive amounts of health care data to function effectively. Current laws, such as the Health Insurance Portability and Accountability Act (HIPAA), oversee the protection and sharing of medical data. However, HIPAA was not designed with AI in mind. New frameworks may be needed to manage the complexities AI introduces, like the integration of non-traditional data sources and real-time analytics.Â
Congress has not passed specific legislation focused on AI data privacy in health care, but there are relevant discussions. Senate Majority Leader Chuck Schumer (D-NY) has taken a leading role in shaping U.S. policy around the use of AI through the formation of bipartisan AI task forces focused on crafting comprehensive legislation to address the rapid advancements in AI, including its implications for health care. Schumer has expressed concern over the risks associated with AI in health care, particularly regarding patient data privacy, potential algorithmic bias in diagnostic tools, and the need for transparency in AI-driven decision-making. His approach seeks to balance the promise of AI in improving health outcomes with the need for safeguards to protect patients and ensure equitable access to these advancements.Â
The House Energy and Commerce Committee, chaired by Rep. Cathy McMorris Rodgers (R-WA), held several hearings focusing on AI in health care. The hearings are part of the Committee’s broader effort to understand and shape the role of emerging technologies in the health sector. The discussions centered on the potential benefits AI could bring to patient care, including improved diagnostic accuracy, faster drug development, and enhanced health care access, particularly in rural and underserved areas. (https://www.maceradrinks.com/) Â The hearings also delved into the risks and challenges associated with integrating AI into health care systems. Key concerns discussed included the need for stringent data privacy protections, preventing algorithmic bias that could lead to health care disparities, and ensuring AI tools are transparent and explainable to both patients and providers.Â
Safety and AccountabilityÂ
Ensuring AI-driven medical technologies are safe is critical. The Food and Drug Administration (FDA) regulates medical devices, including certain AI systems. However, AI presents unique challenges due to its evolving nature, where algorithms may change after initial approval. Current regulations do not always account for this, and Congress may need to create new frameworks to ensure continuous monitoring.Â
One such framework may be legislation such as the Artificial Intelligence for the Armed Forces Act which would encourage the use of AI while ensuring safety standards. While this bill focuses more on defense than health care, Congress could use similar principles to shape legislation addressing health care-specific AI, requiring continuous monitoring and real-time updates to safety regulations.Â
An additional approach could be The Advancing American AI Act, which passed the Senate in 2021. This bill calls for creating government standards for AI across sectors, including health care. Standardization could lead to the development of a more uniform way to evaluate the safety of AI systems in medical settings.Â
Bias and FairnessÂ
AI in health care can perpetuate biases if it is trained on skewed or incomplete data. This is particularly concerning when AI tools are used to diagnose or make treatment decisions, potentially exacerbating disparities in care for marginalized populations.Â
On September 24, 2024, Senator Ed Markey (D-MA) introduced legislation to address bias in the use of AI. The Artificial Intelligence Civil Rights Act would prohibit developers from offering or using algorithms that discriminate based on characteristics like race or gender. Additionally, the FDA has acknowledged the issue of bias in AI, proposing guidelines that developers must follow to ensure their algorithms are trained on diverse datasets. Congress may push for legislation that mandates transparency in developing AI health care tools to minimize biases.Â
Ethical Standards and Human OversightÂ
AI optimizes many aspects of health care, but ethical concerns remain, especially when AI is involved in patient care decisions. AI is already assisting health care professionals in diagnosing diseases, planning treatments, predicting outcomes, and managing population health. Congress may consider regulations requiring human oversight in critical health care decisions to prevent AI from being the sole decision-maker. Additionally, the need for ethical guidelines to prevent AI from prioritizing efficiency over patient well-being is essential.Â
While there is no AI-specific health care legislation addressing ethics, the Biden Administration’s AI Bill of Rights emphasizes the need for meaningful human oversight of AI decisions and proposes guidelines to ensure AI technologies are used ethically. This could lead to future regulations that enforce human oversight in health care AI applications.Â
Â
Current Legislative EffortsÂ
Though Congress has yet to pass comprehensive AI health care-specific legislation, several bills touch on important aspects of AI regulation. One key bill is the National AI Initiative Act of 2020 which would establish a national AI strategy. While not enacted, the bill lays the groundwork for further sector-specific regulations, including health care. The AI in Government Act of 2020 also would seek to improve AI use across federal agencies and could influence how AI is implemented in federally funded health care programs.Â
ConclusionÂ
AI holds tremendous promise for improving health care but also brings new risks requiring legislation and regulatory oversight. While Congress has yet to enact specific legislation targeting AI in health care, discussions are underway. The focus on data privacy, safety, bias, and ethical standards will likely guide future action. By balancing innovation with patient protection, Congress can shape a health care system where AI enhances care while safeguarding rights and well-being.Â

Congress returns just in time to consider a bipartisan agreement to keep the government funded through December. On the other side of Pennsylvania Avenue, Ukrainian President Volodymyr Zelenskyy is coming to meet with President Biden and Vice President Harris about the state of the war against Russia. Let’s see what this consequential week holds. Welcome to the Week Ahead!Â
The Administration Â
Yet Another Obamacare ChallengeÂ
The Department of Health and Human Services (HHS) has requested the Supreme Court review a court decision that partially blocked enforcement of the Affordable Care Act (ACA) mandate for employers to cover certain preventive health services at no-cost. At issue in this challenge is the ruling by the 5th Circuit Court of Appeals that members of the U.S. Preventative Services Task Force (USPSTF)were not properly appointed under the U.S. Constitution’s appointments clause (governing the appointment of Executive Branch officials). The ACA requires that private insurers cover at no cost services that the USPSTF has rated either “A” or “B” (meaning the panel finds that the services have a substantial or moderate net health benefit.)Â
Â
Will the Supreme Court take up this challenge, and if they do, how will the new Administration respond?  We will also be watching to see to what extent fights about the ACA impact the election, especially with Republican Vice Presidential candidate J.D. Vance’s recent reopening the issue on the campaign trail.Â
Â
FTC Sues PBMsÂ
In other health care legal news, the Federal Trade Commission (FTC) announced legal action against the three largest pharmacy benefits managers (PBMs), arguing that these entities have engaged in anticompetitive practices designed to increase profits from insulin. Â
The Biden Administration has made addressing concerns about anti-competitive economic practices a top priority, and the FTC has been a leader in those efforts. The agency has faced both internal and external criticism for being too political, but Lina Khan, the agency’s chair, has won bipartisan praise from at least one Republican – J.D. Vance. This means regardless of who wins the White House in November, Chair Khan will have at least the potential for an ally in either Administration.Â
The Senate Â
Rare Pediatric Disease Priority Review Voucher Program Gets HELP Vote Â
The Senate Health Education, Labor, and Pensions Committee will hold a markup on September 26. This markup includes health care legislation such as S. 4583, which would reauthorize the Rare Pediatric Disease Priority Review Voucher Program through September 30, 2024. A similar version of this bill passed out of the House Energy and Commerce Committee in May and both bills have bipartisan support. Â
Legislation to reauthorize the Rare Pediatric Disease Priority Review Voucher Program has garnered bipartisan support in both chambers. However, it has also faced criticism based on concerns that not enough oversight is being done to ensure it is meeting its goal of incentivizing the development of rare pediatric disease treatments. We will be watching to see what the Senate HELP Committee will do in regards to legislation to reauthorize this program. Â
Health Care HearingsÂ
- September 24: Senate Health, Education, Labor and Pensions Committee hearing on Novo Nordisk’s pricing of diabetes and obesity medicationÂ
- September 24: Senate Finance Committee hearing on women’s reproductive health careÂ
- September 25: Senate Homeland Security and Governmental Affairs Committee business meeting, including re: S.4667, the Risk Research Review ActÂ
- September 26: Senate Environment and Public Works Superfund, Waste Management, and Regulatory Oversight Subcommittee hearing on the public health impacts of PFAS exposureÂ
- September 26: Senate Health, Education, Labor, and Pensions Committee executive session to consider legislation Â
The HouseÂ
More Health Care Bills on the Docket Â
Just like last week, the House has several health care bills on its schedule for floor action the week of September 23. This list of bills includes legislation related to pediatric drug development (H.R. 3433) and Medicaid coverage for U.S. service members (H.R. 8108) that just passed out of Energy and Commerce on September 18.Â
Notably absent from the list: Legislation to extend COVID-era telehealth flexibilities, such as the Telehealth Modernization Act (H.R.7623), which also passed out of the Energy and Commerce Committee on September 18. As a reminder, those flexibilities are set to expire at the end of the year. We will be watching for action on this when Congress returns in November.Â
Healthcare HearingsÂ
- September 25: House Veterans’ Affairs Committee hearing on supporting the Veteran caregiver communityÂ
- September 26: House Oversight and Accountability Health Care and Financial Services Subcommittee hearing on recent Biden Administration action related to Medicare Part DÂ Â
There You Have ItÂ
Election season is in full swing, with early voting already underway in three states! Are you registered to vote? If not, get registered here. Make it a great week! Â
On September 20, 2024 the Medicaid and CHIP Payment and Access Commission (MACPAC) held the second and final day of their September 2024 Public meeting. Session themes included work on residential services for youth with behavioral health needs, managed care external quality review, work related to care for justice- involved youth, and themes from the Hospital Payment Index Technical Expert Panel (TEP). Read more.Â
On September 20, 2024, the Medicare Payment Advisory Commission (MedPAC) met in their first meeting of the 2024-2025 cycle. The September MedPAC meeting is usually filled with aspirational directions for the year or follow-up from last year. The Commission discussed three topics: beneficiary cost sharing in critical access hospitals (CAHs), rural provider quality, and an overview of the Medicare context chapter.Â